Is molecular profiling integral to choice of treatment or simply a source of confusion? Dr. John Marshall speaks to issues that need to be resolved before 'personalized medicine' is practice-ready.

FDA Commissioner Margaret Hamburg, MD, talks with Medscape at the National Health Research Forum in Washington, DC.

Drs. D. Ross Camidge and Giorgio Scagliotti highlight the emerging data in ALK-positive lung cancer that will change the playing field in clinical practice.

Cediranib, bevacizumab, and novel antiangiogenic agents continue to improve survival in first-line and recurrent ovarian cancer, as reported by Dr. Stanley Kaye from ECC 2013.

American Psychiatric Association President Dr. Jeffrey Lieberman on how government policies are out of sync with our country's medical needs.

Dr. Kathy Miller reports on the potential harm that may come as a result of CIGNA's new policy that no genetic testing will be covered unless the patient first sees a genetic counselor.

Farzad Mostashari, MD, reflects on his tenure as the National Coordinator for Health Information Technology in an interview with Medscape Editor-in-Chief Eric J. Topol, MD.

The evidence for the benefits of low-dose aspirin in primary and secondary prevention of colorectal cancer is so compelling that it has convinced CRC specialist Dr. David Kerr to take 100 mg daily.

What's in a word? Enough to 'set your hair on fire' if the word is cancer, says Dr. George Lundberg, who comments on the importance of not calling a lesion 'cancer' when it is not.

Dr. Bruce Cheson forecasts that the Sunshine Act, requiring physicians to disclose most payment and gifts from industry over $10, will bring showers of misinterpretation and could hinder research.